

**Patient: MS SEQ2, POSITIVE**

DOB: N/A Age: 266

Gender: U

**Patient Identifiers: 558818**

**Visit Number (FIN): 582079**

Client: ARUP Physician Services  
321 TESTING ANSR EXTRACT  
Salt Lake City, NY 84108

Physician: DR TEST

ARUP Test Code: 3000148

Collection Date: 10/11/2019


Received in lab: 10/28/2019

Completion Date: 10/28/2019

**Interpretation: SCREEN POSITIVE**  
**Follow-up for risk of TRISOMY 18 is suggested**


**Neural Tube Defects (NTD): Negative**

Risk before test: 1 in 1030  
Risk after test: <1 in 10000




**Down syndrome (DS): Negative**

Risk before test: 1 in 923  
Risk after test: 1 in 13500



**Trisomy 18 (T18): Positive**

Risk before test: 1 in 3600  
Risk after test: >1 in 91



**Comments:**

The risk of an open neural tube defect is less than the screening cut-off.

The risk of Down syndrome is less than the screening cut-off.

The risk of trisomy 18 is greater than the screening cut-off. Other outcomes of positive screens include normal pregnancy, increased risk for miscarriage, fetal demise, low birth weight and preterm labor, nonchromosomal anomalies and genetic syndromes. Recalculating Trisomy 18 risk based on second trimester dating is not recommended as Trisomy 18 fetuses may be small for gestational age. Genetic counseling regarding the risks and benefits of cell-free DNA (NIPT) and fetal diagnostic testing is suggested. If you have questions regarding this screen, please call Genetics at 800-242-2787 ext 2141.

Marker	Measurement	MoM
AFP	36 ng/mL	0.91
uE3	1.52 ng/mL	1.02
hCG	3585 IU/L	0.20
DIA	89 pg/mL	0.43
PAPP-A	298.3 ng/mL	0.29
NT	2.30 mm	1.20



Patient: MS SEQ2, POSITIVE  
ARUP Accession: 19-284-144116  
4070

# Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Patient: MS SEQ2, POSITIVE | Date of Birth: Not Provided | Gender: U | Physician: DR TEST  
Patient Identifiers: 558818 | Visit Number (FIN): 582079

PAPP-A Maternal Compliance Statement: Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: [aruplab.com/CS](http://aruplab.com/CS)

Maternal Screen Interpretation Compliance Statement: Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: [aruplab.com/CS](http://aruplab.com/CS)

## Patient Information Used in Risk Calculations

Maternal Age at Delivery:	27.8 yr
Maternal Weight:	79.0 kg
Gestational Age at Draw:	18 wks, 0 days
Number of Fetuses:	Singleton
Maternal Race:	Nonblack
Medication-Dependent Maternal Diabetes:	No
Current Smoker:	Yes
Family History of Neural Tube Defects:	No
Family History of Aneuploidy:	No
Specimen:	Initial sample
Crown Rump Length:	78.8 mm
Sonographer Certification #:	P15936
Sonographer Name:	Lacroix, Brand
Ultrasound Date:	09-10-19

## Reference Information

The following links or information offer complete and up to date information about this test, including access to ARUP Consult™ disease topics and other supplemental resources.

- [Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A](http://ltd.aruplab.com/tests/pub/3000148)  
(<http://ltd.aruplab.com/tests/pub/3000148>)
- [Prenatal Aneuploidy Screening](https://www.aruplab.com/genetics/tests/prenatal)  
(<https://www.aruplab.com/genetics/tests/prenatal>)
- [Additional Technical Information](http://ltd.aruplab.com/Tests/Pdf/311)  
(<http://ltd.aruplab.com/Tests/Pdf/311>)



Patient: MS SEQ2, POSITIVE  
ARUP Accession: 19-284-144116  
4070